Vindesine in refractory multiple myeloma. 1986

H van der Lelie, and E Monasch, and H G Pegels, and A E von dem Borne

In 12 of 18 patients with multiple myeloma refractory to treatment with the combination of vincristine, melphalan, cyclophosphamide, and prednisone, favorable results were obtained by replacing vincristine in this combination with vindesine. Although only three patients showed marked reductions (greater than 50%) of myeloma protein, this treatment, which was well tolerated, was also clearly beneficial to the other responding patients, thus postponing the need for more toxic treatment programs.

UI MeSH Term Description Entries
D008297 Male Males
D008558 Melphalan An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen. Medphalan,Merphalan,Phenylalanine Mustard,Sarcolysine,Sarkolysin,4-(Bis(2-chloroethyl)amino)phenylalanine,Alkeran,L-PAM,Mustard, Phenylalanine
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009101 Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. Myeloma, Plasma-Cell,Kahler Disease,Myeloma, Multiple,Myeloma-Multiple,Myelomatosis,Plasma Cell Myeloma,Cell Myeloma, Plasma,Cell Myelomas, Plasma,Disease, Kahler,Multiple Myelomas,Myeloma Multiple,Myeloma, Plasma Cell,Myeloma-Multiples,Myelomas, Multiple,Myelomas, Plasma Cell,Myelomas, Plasma-Cell,Myelomatoses,Plasma Cell Myelomas,Plasma-Cell Myeloma,Plasma-Cell Myelomas
D009194 Myeloma Proteins Abnormal immunoglobulins characteristic of MULTIPLE MYELOMA. M Components,Proteins, Myeloma
D011241 Prednisone A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver. Dehydrocortisone,delta-Cortisone,Apo-Prednisone,Cortan,Cortancyl,Cutason,Dacortin,Decortin,Decortisyl,Deltasone,Encorton,Encortone,Enkortolon,Kortancyl,Liquid Pred,Meticorten,Orasone,Panafcort,Panasol,Predni Tablinen,Prednidib,Predniment,Prednison Acsis,Prednison Galen,Prednison Hexal,Pronisone,Rectodelt,Sone,Sterapred,Ultracorten,Winpred,Acsis, Prednison
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

H van der Lelie, and E Monasch, and H G Pegels, and A E von dem Borne
February 1981, European journal of cancer,
H van der Lelie, and E Monasch, and H G Pegels, and A E von dem Borne
June 1983, European journal of cancer & clinical oncology,
H van der Lelie, and E Monasch, and H G Pegels, and A E von dem Borne
January 2020, Therapeutic advances in hematology,
H van der Lelie, and E Monasch, and H G Pegels, and A E von dem Borne
November 2019, The New England journal of medicine,
H van der Lelie, and E Monasch, and H G Pegels, and A E von dem Borne
January 1984, The Netherlands journal of medicine,
H van der Lelie, and E Monasch, and H G Pegels, and A E von dem Borne
April 2021, British journal of haematology,
H van der Lelie, and E Monasch, and H G Pegels, and A E von dem Borne
December 2001, Seminars in oncology,
H van der Lelie, and E Monasch, and H G Pegels, and A E von dem Borne
August 2022, The New England journal of medicine,
H van der Lelie, and E Monasch, and H G Pegels, and A E von dem Borne
November 2022, The New England journal of medicine,
H van der Lelie, and E Monasch, and H G Pegels, and A E von dem Borne
June 2024, Annals of hematology,
Copied contents to your clipboard!